Infectious Diseases

da_id_section.jpg

Communicable diseases continue to be a major cause of morbidity and mortality around the world. Through our research in Infectious Diseases (ID), Novartis is committed to developing new treatments for bacterial and viral infections.

Viruses take over a host cell in order to propagate their genomes. Our ID research strategy is to develop more effective treatments against infection by better understanding the molecular mechanisms of viral replication. To block virus spread, we target pathogen-encoded proteins, as well as the cellular factors that are required for infection.

Bacterial resistance to available antibiotics is a growing problem. By conducting fundamental research into the mechanisms of drug susceptibility, we are developing new classes of antibacterial agents with novel mechanisms of action. These will provide new options in the fight to combat multi-drug resistant infections.

Our ID research concentrates on viral infections, such as the hepatitis C virus, respiratory syncytial virus, and human cytomegalovirus, as well as on bacterial pathogens, such as Clostridium difficile, Staphylococcus aureus, and Pseudomonas aeruginosa.

 

Selected Publications

Deletion of the beta-Acetoacetyl Synthase FabY in Pseudomonas aeruginosa Induces Hypoacylation of Lipopolysaccharide and Increases Antimicrobial Susceptibility. Six DA1, Yuan Y, Leeds JA, Meredith TC. Antimicrob Agents Chemother, 2014. 58(1): p. 153-61.

KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D. (2014) PLoS Pathog. 2014 Jan;10(1):e1003847.

Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Chandriani S, Skewes-Cox P, Zhong W, Ganem DE, Divers TJ, Van Blaricum AJ, Tennant BC, Kistler AL. 2013. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):E1407-15.

Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of beta-ketoacyl acyl carrier protein synthases. Yuan Y1, Sachdeva M, Leeds JA, Meredith TC. J Bacteriol, 2012. 194(19): p. 5171-84.

Identification of elongation factor G as the conserved cellular target of argyrin B. Nyfeler B1, Hoepfner D, Palestrant D, Kirby CA, Whitehead L, Yu R, Deng G, Caughlan RE, Woods AL, Jones AK, Barnes SW, Walker JR, Gaulis S, Hauy E, Brachmann SM, Krastel P, Studer C, Riedl R, Estoppey D, Aust T, Movva NR, Wang Z, Salcius M, Michaud GA, McAllister G, Murphy LO, Tallarico JA, Wilson CJ, Dean CR. PLoS One, 2012. 7(9): p. e42657.